News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcobra (ADHD) To Release Second Quarter 2014 Results And Host Investor Conference Call And Webcast On Monday, August 11


8/1/2014 11:16:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the second quarter of 2014 and will host a corporate update conference call and webcast on Monday, August 11, 2014.

Conference Call & Webcast

Monday, August 11 @ 8:30am Eastern Time/5:30am Pacific Time

Domestic: 855-469-0611
International: 484-756-4341
Passcode: 78699281
Webcast: www.alcobra-pharma.com
Replays, available through August 25, 2014
Domestic: 855-859-2056
International: 404-537-3406
Passcode: 78699281

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies in adults with ADHD and has completed enrollment in a Phase III study in adults with ADHD. The company is conducting separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Alcobra Ltd. logo


Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Alcobra
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES